Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Solid Biosciences Inc.NASDAQ: SLDB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$56.34M, compared with -$38.81M a year earlier. Trailing-twelve-month EBITDA was -$190.1M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of -$142.67M (+17.4%) for the fiscal year ending Dec 2026, a step up from the -41.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$56.34M-14.2% QoQ
- Last fiscal yearDec 2025
- -$172.69M-41.7% YoY
- LTMMar 2026
- -$190.1M-38.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.2% | — | — |
| 1 year | -41.7% | +17.4% | +59.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (172.69M) USD
- Year-over-year change
- -41.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (172.69M) | -41.7% |
| FY2024 | 2024-12-31 | (121.9M) | -30.5% |
| FY2023 | 2023-12-31 | (93.43M) | +3.5% |
| FY2022 | 2022-12-31 | (96.87M) | -39.9% |
| FY2021 | 2021-12-31 | (69.22M) | — |
EBITDA vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 EBITDA of -$190.1M is the 8th highest of the 10 companies compared; the peer median is -$95.45M.
- Its year-over-year change of -38.9% is the 9th highest of 10, against a peer median of +3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -$75.99M | +22.0% | — | — | |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Sep 2026 | -$200.94M | -29.7% | — | — | |
| LTM Jun 2026 | -$495.35M | -20.6% | — | — | |
| Peer median (excluding SLDB) | -$95.45M | +3.9% | — | 68.6% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| Weighted Avg Shares | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
| Weighted Avg Shares (Diluted) | 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.